Licensing status

Publication and contact information

Infectious disease


Influenza A virus matrix protein 2 (M2)

In vitro studies identified M2 inhibitors that could help treat amantadine-resistant influenza. The S31N M2 mutation in the influenza virus results in resistance to first-generation M2 inhibitors, including amantadine. In Xenopus laevis oocytes expressing the S31N M2 mutant protein, amantadine derivatives with a CH2-heteroaryl group conjugated to the drug's amine group inhibited the M2 proton channel. In a cellular assay using an influenza virus expressing the S31N mutant, derivatives of the new M2 inhibitor blocked viral replication. Next steps include testing in animals.

SciBX 6(4); doi:10.1038/scibx.2013.90
Published online Jan. 31, 2013

Patent application filed; licensed to InfluMedix Inc.; available for licensing

Wang, J. et al. Proc. Natl. Acad. Sci. USA; published online Jan. 9, 2013;
Contact: William F. DeGrado, University of California, San Francisco, Calif.

Contact: Yibing Wu, same affiliation as above